GM-CSF versus G-CSF: Engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation

Cytotherapy

Volumn 4, Issue 6, 2002, Pages 531-538

  Zumberg, M S ^a,b   Leather, H L ^a,b   Nejame, C ^a,b   Meyer, C ^a,b   Wingard, J R ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Engraftment; G CSF; GM CSF; Growth factor; Stem cell transplant

Indexed keywords

ALKYLATING AGENT; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BUSULFAN; CARBOPLATIN; CD34 ANTIGEN; CEFEPIME; CEFTAZIDIME; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA; VANCOMYCIN; VINCRISTINE;

ADULT; AGED; ANAMNESIS; ARTICLE; BACTERIAL INFECTION; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAFT REJECTION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKAPHERESIS; MALE; MULTIPLE MYELOMA; MYCOSIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; TESTIS CANCER; THROMBOCYTE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INFECTION; X RAY;

EID: 0036929698     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402761624692     Document Type: Article

References (36)

1. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit. J Clin Oncol 1997;15:451-7.
2. To LB, Roberts MM, Haylock DN et al. Comparison of hematological recovery times and supportive care requirements for autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992;9:277-84.
3. Schmitz N, Linch DC, Dreger P et al. A randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996;34:3563-7.
4. Advani R, Chao NJ, Homing SJ et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation. Ann Intern Med 1992;116:183-9.
5. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral blood stem-cell transplant: Neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994;12:661-70.
6. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339(8794):640-4.
7. Bolwell BJ, Fishleder A, Andresen SW et al. G-CSF primed peripheral blood progenitor cells autologous bone marrow transplantation: Parameters affecting bone marrow engraftment. Bone Marrow Transplant 1993;12:609-14.
8. Bolwell BJ, Goormastic M, Yanssems T et al. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and enhancing recovery after autologous bone marrow transplant. Bone Marrow Transplant 1997;14:913-18.
9. Henon PR, Liang H, Beck-Wirth G et al. Comparisons of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplantation. Bone Marrow Transplant 1992;9:285-91.
10. Beyer I, Schwella N, Zingsem J et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995;13:1328-35.
11. Ager S, Scott MA, Mahenolra P et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: A retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995;16:79-83.
12. Legros M, Fleury J, Bay JO et al. rhGM-CSF vs. placebo following rhGM-CSF-mobilized PBPC transplantation: A Phase III double blind randomized trial. Bone Marrow Transplant 1997;19:209-13.
13. Recchia F, Accorsi P, Bonfini T et al. Randomized trial of sequential administration of G-CSF and GM-CSF versus G-CSF alone following peripheral blood progenitor cell autograft in solid tumors. J Interferon Cytokine Res 2000;20:171-7.
14. Tarella C, Castellino C, Locatelli F et al. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: Evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998;21:401-7.
15. Brandt SJ, Peters WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1985;318:869-76.
16. Kodo H, Tajika K, Takahashi S et al. Acceleration of neutrophilic granulocyte recovery after bone marrow transplantation by administration of recombinant human granulocyte colony-stimulating factor. Lancet 1988;2(8601):38-9.
17. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte-colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1988;2(8688):891-5.
18. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8.
19. Rabinowe SN, Nemunaitis J, Armitage J et al. The impact of myeloid growth factors on engraftment following autologous bone marrow transplantation for malignant lymphoma. Semin Hematol 1991;28:6-16.
20. Khwaja A, Linch DC, Goldstone AH et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplant for malignant lymphoma: A British National Lymphoma investigation double blind, placebo-controlled trial. Br J Hematol 1992;82:317-23.
21. Stahel RA, Jost LM, Cerny T et al. Randomized study of recombinant human granulocyte colony-stimulating factor, after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994;12:1931-8.
22. Linch DC, Milligan DW, Winrfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial. Br J Hematol 1997;99:933-8.
23. Gianni AM, Bregini M, Siena S et al. Rapid and complete hematological reconstitution following combined transplantation of autologous blood and bone marrow cells: A changing role for high dose chemo-radiotherapy. Hematol Oncol 1989;7:139-48.
24. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993;81:1709-19.
25. Jansen J, Thompson EM, Hanks S et al. Hematopoietic growth factor after autologous peripheral blood transplantation: Comparison of G-CSF and GM-CSF. Bone Marrow Transplant 1999;23:1251-6.
26. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation, a prospective, randomized trial. J Clin Oncol 1995;13:1323-7.
27. Brice P, Divine M, Marolleau JP et al. Comparison of autografting mobilized peripheral blood stem cells with and without granulocyte colony-stimulating factor in malignant lymphomas. Bone Marrow Transplant 1994;14:51-5.
28. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994;87:825-31.
29. Cortelazzo S, Viero P, Bellavita P et al. Granulocyte colony stimulating factor following peripheral-blood progenitor transplant in non-Hodgkin lymphoma. J Clin Oncol 1995;13:935-41.
30. Shimazaki C, Oku N, Uchimaya H et al. Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral progenitor cell transplantation. Bone Marrow Transplant 1994;13:271-5.
31. Bolwell BJ, Pohlman B, Andresen S et al. Delayed G-CSF after autologous progenitor cell transplantation: A prospective randomized trial. Bone Marrow Transplant 1998;21:369-73.
32. Faucher C, Le Coroller AG, Chabannon et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF primed blood stem cells: A randomized study. Bone Marrow Transplant 1996;17:533-6.
33. Dix SO, McGuirk JP, Barnhart et al. Routine versus risk-adapted administration of colony stimulating factors following autologous peripheral blood stem cell transplant (AutoPBSCT). Biol Blood Marrow Transplant 2001;7:70 [Abstract 24].
34. Neumantis J. The use of cytokines during blood and marrow transplantation. In: Wingard JR, Demetri GD editors. Clinical Applications of Cytokines and Growth Factors. Norwell, MA: Kluwer Academic Publishers, 1999:386.
35. Antman K, Ayash L, Wheeter C et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatinum with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992;10:102-10.
36. Drug Topics Red Book. Montvale, NJ: Medical Economics Co., 2000.